Royalty Pharma plc (NASDAQ:RPRX) Shares Acquired by Eaton Vance Management


Share on StockTwits

Eaton Vance Management lifted its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX) by 55.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 862,140 shares of the biopharmaceutical company’s stock after acquiring an additional 308,143 shares during the quarter. Eaton Vance Management owned about 0.22% of Royalty Pharma worth $43,150,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also bought and sold shares of RPRX. Vantage Consulting Group Inc acquired a new position in shares of Royalty Pharma during the 4th quarter valued at $1,074,938,000. Morgan Stanley increased its stake in Royalty Pharma by 154.1% during the 4th quarter. Morgan Stanley now owns 23,798,081 shares of the biopharmaceutical company’s stock worth $1,191,094,000 after buying an additional 14,431,463 shares during the period. Siguler Guff Advisers LLC purchased a new stake in Royalty Pharma during the 4th quarter worth $338,436,000. FMR LLC increased its stake in Royalty Pharma by 37.1% during the 4th quarter. FMR LLC now owns 24,942,548 shares of the biopharmaceutical company’s stock worth $1,248,374,000 after buying an additional 6,754,244 shares during the period. Finally, BlackRock Inc. increased its stake in Royalty Pharma by 142.6% during the 4th quarter. BlackRock Inc. now owns 9,053,545 shares of the biopharmaceutical company’s stock worth $453,128,000 after buying an additional 5,321,913 shares during the period. Institutional investors and hedge funds own 40.85% of the company’s stock.

RPRX opened at $41.57 on Thursday. The company has a 50-day moving average of $45.34 and a 200-day moving average of $44.67. Royalty Pharma plc has a 1-year low of $34.80 and a 1-year high of $56.50. The company has a debt-to-equity ratio of 0.59, a current ratio of 10.31 and a quick ratio of 10.31.

Royalty Pharma (NASDAQ:RPRX) last released its earnings results on Wednesday, February 17th. The biopharmaceutical company reported $0.28 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.70 by ($0.42). The firm had revenue of $572.00 million for the quarter, compared to the consensus estimate of $486.89 million. On average, sell-side analysts anticipate that Royalty Pharma plc will post 2.44 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Monday, March 15th. Stockholders of record on Friday, February 19th were given a $0.17 dividend. The ex-dividend date of this dividend was Thursday, February 18th. This represents a $0.68 annualized dividend and a dividend yield of 1.64%. This is an increase from Royalty Pharma’s previous quarterly dividend of $0.15.

In other Royalty Pharma news, Director Henry A. Fernandez acquired 25,700 shares of the stock in a transaction that occurred on Thursday, February 25th. The stock was acquired at an average price of $46.83 per share, with a total value of $1,203,531.00. Following the transaction, the director now directly owns 8,713 shares in the company, valued at $408,029.79. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, EVP James F. Reddoch sold 43,927 shares of the business’s stock in a transaction dated Monday, March 22nd. The shares were sold at an average price of $46.32, for a total transaction of $2,034,698.64. Following the sale, the executive vice president now directly owns 3,000 shares of the company’s stock, valued at approximately $138,960. The disclosure for this sale can be found here. Insiders sold a total of 268,927 shares of company stock valued at $12,596,199 in the last three months. Insiders own 2.50% of the company’s stock.

Separately, Zacks Investment Research downgraded shares of Royalty Pharma from a “buy” rating to a “hold” rating in a research note on Friday, February 5th. Six equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Royalty Pharma currently has an average rating of “Hold” and a consensus target price of $51.89.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.

Featured Story: Should You Consider an Index Fund?

Institutional Ownership by Quarter for Royalty Pharma (NASDAQ:RPRX)

Receive News & Ratings for Royalty Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Royalty Pharma and related companies with MarketBeat.com's FREE daily email newsletter.